Tag: Aprepitant

As many as 80% of patients receiving highly emetogenic chemotherapy experience acute nausea and vomiting without prophylactic antiemetic treatment. A key medication in combating this side effect is Aprepitant, which is a prime example of an NK1 receptor antagonist.

According to the Multinational Association of Supportive Care in Cancer (MASCC)/European Society for Medical Oncology (ESMO), NK antagonists are strongly recommended for preventing chemotherapy-induced nausea and vomiting (CINV). A primary and widely used example of an NK antagonist is aprepitant, a medication that targets specific receptors in the brain to block the vomiting reflex.

According to the Annals of Palliative Medicine, up to 80% of patients may experience chemotherapy-induced nausea and vomiting (CINV) without prophylactic therapy. A neurokinin receptor antagonist is a class of medication developed to help prevent this distressing side effect.